Search

Your search keyword '"Ratziu, Vlad"' showing total 538 results

Search Constraints

Start Over You searched for: Author "Ratziu, Vlad" Remove constraint Author: "Ratziu, Vlad" Journal journal of hepatology Remove constraint Journal: journal of hepatology
538 results on '"Ratziu, Vlad"'

Search Results

1. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

5. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis

6. A global research priority agenda to advance public health responses to fatty liver disease

11. NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned

14. GS-006 Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial

16. LBO-002 Efruxifermin significantly reduced liver fibrosis in MASH patients with F2-F3 fibrosis, with sustained improvement in liver injury and resolution of steatohepatitis over 96 weeks (HARMONY phase 2b study)

18. GS-002 48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204

24. SAT-201 Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests

26. WED-206 Nash-FibroTest for the diagnosis of significant fibrosis, in severe obesity treated with bariatric surgery and external non-linear trajectories of test’ components among obesity classes in a large US population

27. FRI-371 Undetectable HDV RNA at 24 weeks of treatment with combination therapy is an important predictor of maintained response off-therapy

28. FRI-208 qBallooning: AI-based ballooned hepatocyte detection and quantification by second harmonic generation/two photon excitation microscopy

32. THU-458 No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC

33. LBP-003 Semaglutide achieves resolution of metabolic dysfunction-associated steatohepatitis via modulation of multiple pathogenic pathways: insights from human and animal studies

36. LBP-036 Final results from the phase 3 REGENERATE trial evaluating the effects of obeticholic acid in patients with pre-cirrhotic fibrosis due to metabolic dysfunction-associated steatohepatitis

42. From the Editor’s Desk...

43. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

44. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

46. From the Editor’s Desk...

48. Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions

50. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Catalog

Books, media, physical & digital resources